Genomics-based drug discovery offers great potential for the development of targeted therapies that can offer new and better treatment options for patients. By utilising genetic and biomarker information, this approach allows us to gain insights into the fundamental causes of diseases. But this growing field is not without its challenges.
In our latest whitepaper, we explore the hurdles associated genomics-based drug discovery, including limited recontactability, insufficient availability of multi-omics datasets, inadequate diversity in data, and the difficulties in scaling research for rare diseases. By tackling these obstacles head-on and presenting viable strategies to overcome them, this whitepaper seeks to provide solutions for driving precision medicine forward.
Download today to learn more: